

STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page1/line 2–3	Title
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page2/line 59–62	Abstract/Paragraph4
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page3–4/line 69–112	Introduction /Paragraph 1–3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 4/ Line 113–119	Introduction / Paragraph 4
Methods				
Study design	4	Present key elements of study design early in the paper	Page 4/ Line 126–130	Methods / Paragraph1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 4/ Line 126–130; Page 5–6/ Line 163–174	Methods / Paragraph1, 5
Participants	6	(a) Cohort study —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study —Give the eligibility criteria, and the sources and methods of selection of participants	Page 5/ Line 138–151	Methods / Paragraph2–3
		(b) Cohort study —For matched studies, give matching criteria and number of exposed and unexposed Case-control study —For matched studies, give matching criteria and the number of controls per case	N/A	N/A (Not matched study)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 5–6/ Line 162–174	Methods / Paragraph5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6–7/ Line 179–206	Methods / Paragraph6–9
Bias	9	Describe any efforts to address potential sources of bias	Page 6/ Line 171–174	Methods / Paragraph5
Study size	10	Explain how the study size was arrived at	Page 5/ Line 133–135	Methods / Paragraph1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 6–7/ Line 179–206	Methods / Paragraph6–9

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 7/ Li ne 210–220	Met hods / Par agr aph 10
		(b) Describe any methods used to examine subgroups and interactions	Page 7/ Li ne 210–220	Met hods / Par agr aph 10
		(c) Explain how missing data were addressed	N/A	Nb mi ssi ng dat a
		(d) Cohort study —If applicable, explain how loss to follow-up was addressed Case-control study —If applicable, explain how matching of cases and controls was addressed Cross-sectional study —If applicable, describe analytical methods taking account of sampling strategy	Page 7/ Li ne 210–220	Met hods / Par agr aph 10
		(e) Describe any sensitivity analyses	Page 7/ Li ne 210–220	Met hods / Par agr aph 10
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 4/ Li ne 126–130	Met hods / Par agr aph1
		(b) Give reasons for non-participation at each stage	Page 4/ Li ne 126–130	Met hods / Par agr aph1
		(c) Consider use of a flow diagram	Page 4/ Li ne 126–130	Met hods / Par agr aph1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 7/ Li ne 226–230	Resul ts/Par agr aph1
		(b) Indicate number of participants with missing data for each variable of interest	N/A	Nb mi ssi ng dat a
		(c) Cohort study —Summarise follow-up time (eg, average and total amount)	Page 4/ Li ne 126–130	Met hods / Par agr aph1
Outcome data	15*	Cohort study —Report numbers of outcome events or summary measures over time	Page 7–8/ Li ne 226–247	Resul ts/Par agr aph1–2
		Case-control study —Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		Cross-sectional study —Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 8/ Li ne 251–257	Resul ts/Par agr aph3
		(b) Report category boundaries when continuous variables were categorized	Page 8/ Li ne 234–247	Resul ts/Par agr aph2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	Nb tr ansl at i ng
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 8/ Li ne 251–257	Resul ts/Par agr aph3
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 8/ Li ne 261–264	Di sussi on/Par agr aph1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11/ Li ne 344–346, 349–354	Di sussi on/Par agr aph6–7

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 9–11/ Li ne 293–343	Discussion/Paragraph 4–5
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11–12/ Li ne 343–364	Conclusion/ Paragraph 1
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 12/ Li ne 368–369	Acknowledgments/Paragraph 1

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: <https://dx.doi.org/10.21037/qims-23-321>

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copy editing and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.